Camurus announced that the US FDA has accepted the resubmission of the New Drug Application (NDA) for CAM2029, an extended-release octreotide injection for treating acromegaly. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of December 18, 2026. This follows a previous Complete Response Letter related to manufacturing inspection issues, which have since been resolved without concerns about the drug's safety or efficacy. CAM2029 is already approved in the EU and UK and offers once-monthly self-administration via an autoinjector pen, with clinical trials showing superior biochemical control and improved patient outcomes compared to existing treatments. The FDA review outcome will determine its availability in the US market.
Cronos blockchain suffered a $120.4 million exploit when an attacker manipulated the price of TONIC token to borrow funds from Tectonic lending markets. Validators halted the network and rolled back nearly two hours of transactions, restoring $111.2 ...
Pump.fun, a Solana-based memecoin launchpad, has reclaimed the top spot in 24-hour protocol revenue with about $1.23 million in fees, overtaking Pons, a newer competitor that had briefly led earlier in 2026. Pons gained rapid traction by leveraging R...
Boyaa Interactive purchased about 205 Bitcoin for $14.3 million between June and September 2026, increasing its total Bitcoin holdings to approximately 4,316 BTC at an average cost of $68,280 per Bitcoin. The company funded these purchases with cash ...
USDT's control depends on the owner role of its smart contract, notably on Tron where a 2-of-3 multisig wallet controls over half of all USDT tokens. This owner role can blacklist addresses, create or destroy tokens, and pause transfers, but cannot a...
McKesson, a leading pharmaceutical distributor in the US oligopoly, generates over $5 billion in free cash flow and is expanding through its oncology segment, which saw a 31% revenue increase year-over-year. The company is strategically acquiring bus...
